New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
10:00 EDTALB, WPX, TSN, SBH, PFS, PCYC, MSTR, MTDR, MWE, LSTR, ONE, FGP, FDO, DCO, COST, COLM, BOH, AGNC, ZIONOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Albemarle (ALB) upgraded to Buy from Hold at Topeka... American Capital Agency (AGNC) upgraded to Buy from Hold at Wunderlich... Bank of Hawaii (BOH) upgraded to Buy from Neutral at DA Davidson... Columbia Sportswear (COLM) upgraded to Hold from Sell at McAdams Wright... Costco (COST) upgraded to Conviction Buy from Neutral at Goldman... Ducommun (DCO) upgraded to Buy from Neutral at DA Davidson... Family Dollar (FDO) upgraded to Neutral from Underweight at Piper Jaffray... Ferrellgas Partners LP (FGP) upgraded to Neutral from Sell at Citigroup... Higher One (ONE) upgraded to Overweight from Underweight at Piper Jaffray... Landstar System (LSTR) upgraded to Buy from Hold at BB&T... MarkWest Energy (MWE) upgraded to Buy from Hold at Wunderlich... Matador (MTDR) upgraded to Outperform from Market Perform at BMO Capital... MicroStrategy (MSTR) upgraded at JMP Securities... Pharmacyclics (PCYC) upgraded to Outperform from Market Perform at Leerink... Provident Financial (PFS) upgraded at Sterne Agee... Sally Beauty (SBH) upgraded to Buy from Neutral at Citigroup... Tyson Foods (TSN) upgraded to Buy from Hold at Miller Tabak... WPX Energy (WPX) upgraded to Accumulate from Hold at Tudor Pickering... Zions Bancorp (ZION) upgraded at Bernstein.
News For ALB;AGNC;BOH;COLM;COST;DCO;FDO;FGP;ONE;LSTR;MWE;MTDR;MSTR;PCYC;PFS;SBH;TSN;WPX;ZION From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 14, 2014
16:37 EDTMTDRMatador increases FY14 oil production guidance range to 3.2M-3.3M barrels
Subscribe for More Information
16:35 EDTMTDRMatador reports Q3 production up 19% to 1.5 MBOE
Matador Resources provided the following update of its ongoing operations. Matador is pleased to announce its quarterly production results for the three months ended September 30, which were the best quarterly oil equivalent production and quarterly oil production results in the company’s history. Oil equivalent production increased 19% year over year from approximately 1.24 MBOE or an average of about 13,500 BOE per day in 3Q13 to approximately 1.5 MBOE or an average of about 16,100 BOE per day in Q3. Oil equivalent production increased approximately 6% sequentially quarter over quarter from approximately 1.4 MBOE or an average of about 15,400 BOE per day in the second quarter of 2014 and increased 38% from approximately 1.1 MBOE or an average of about 11,900 BOE per day in Q1.
08:43 EDTMTDRMatador upgraded to Accumulate from Hold at KLR Group
Subscribe for More Information
05:58 EDTCOSTCostco debuts in China through Alibaba Tmall platform
Subscribe for More Information
October 13, 2014
12:01 EDTFDOOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INFY YUM FDO HSY
08:05 EDTPCYCBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:09 EDTLSTRLandstar System removed from short-term buy list at Deutsche Bank
Subscribe for More Information
October 10, 2014
17:16 EDTMWEMarkWest Energy files to sell $1.5B of common units
16:17 EDTFDODollar General receives second request from FTC
Subscribe for More Information
08:31 EDTMWEGoldman remains bullish on MLPs
Subscribe for More Information
08:11 EDTFDOFamily Dollar Q4 bad enough to justify merger, says FBR Capital
Subscribe for More Information
07:15 EDTSBHJackson Square reports 10.07% passive stake in Sally Beauty
Subscribe for More Information
October 9, 2014
18:46 EDTMSTRMicroStrategy committed to restructuring plan, sees charges $17.0M-$20.0M
Subscribe for More Information
16:19 EDTFDOFamily Dollar will not provide guidance for FY15
Subscribe for More Information
16:17 EDTFDOFamily Dollar reports Q4 adjusted EPS 73c, consensus 77c
Reports Q4 revenue $2.61B, consensus $2.58B. Reports Q4 SSS up 0.3%. Q4 adjusted results exclude the negative impact on diluted net income per common share of 43c per share related to the Company’s restructuring charges and fees related to its pending merger with Dollar Tree.
10:21 EDTWPXWPX Energy says will explore opportunistic, bolt-on acquisitions
Subscribe for More Information
10:15 EDTWPXWPX Energy sees increasing market cap threefold by 2020
Says about 100 employees chose to accept early exit program. Sees year end employee headcount down about 15% from year end 2013. Says about 70%-80% of capital is oil focused. Says production guidance "in line" with previously provided view. Says expects to increase market capitalization threefold by 2020; says this belief is not reliant on M&A, bolt on acquisitions. Says targeting $12B market cap by 2020. Sees fivefold increase in oil production by 2020. Says bullish longer term for natural gas. Sees nat gas pricing $3.50-$4.50 over next three years, sees oil market at $80.00-$100.00 a barrel. Comments made on the company's strategy rollout conference call. WPX Energy shares are down 4.78% to $20.53 in morning trading.
09:59 EDTWPXWPX Energy sees Q3 adjusted production 1,060-1,073.3 MMcfe/d
Subscribe for More Information
09:56 EDTWPXWPX Energy reaffirms adjusted full-year production guidance
WPX Energy reaffirmed its full-year production guidance ranges, adjusted for its Powder River sale. In the Williston, WPX says its initial result of larger stimulations encouraging. In San Juan Gallup, WPX says it is completing first two 7,500ʹ laterals and that a 3rd rig has been added. Guidance and comments from slides for strategic update.
09:41 EDTCOST, FDOBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use